IXICO upbeat on 2026 as contract wins swell order book

IXICO said it is entering 2026 with an upbeat outlook after its order book climbed 27% since the September year-end to £17.7m, driven by contract wins in Alzheimer’s, Huntington’s and blood‑based biomarkers including a £3.5m phase III Huntington’s contract and £1.2m of Alzheimer’s/biomarker deals. Full-year results showed a return to growth with revenue up 13% to £6.5m, gross margin of 49%, an EBITDA loss narrowed to £1.3m, cash of £3.5m (after a £3.7m raise) and net assets of £11.7m, while management said targeted investment is supporting future expansion. IXICO plans to grow by broadening its clinical-trial imaging services, diversifying its platform and capitalizing on rising biopharma interest in AI and biomarkers—positioning the company to benefit from continued neuroscience trial activity despite wider industry financial conservatism.

Analysis

IXICO reported a 27% increase in its order book since the September 2025 year-end, rising from £13.8m to £17.7m by end-November, led by contract wins in Alzheimer’s, Huntington’s and blood‑based biomarkers including a £3.5m phase III Huntington’s contract in November and £1.2m of Alzheimer’s/biomarker deals in October. Full-year revenue returned to growth, up 13% to £6.5m, gross margin improved to 49% and the EBITDA loss narrowed to £1.3m, while management framed the momentum as supportive of an upbeat 2026 outlook.

The group is targeting revenue diversification by expanding clinical-trial imaging services and broadening its technology platform to capitalize on rising biopharma interest in AI and biomarker tools; IXICO cites Alzheimer’s UK data showing 138 Alzheimer’s drugs in testing, a 9% increase year‑on‑year, as evidence of sustained neuroscience trial activity despite industry financial conservatism. Appointments of senior scientific advisers reinforce the company’s strategy to strengthen technical credibility with sponsors and device partners.

Financially the picture is mixed: cash was £3.5m after a £3.7m raise earlier in the year and net assets were £11.7m, but the company remains EBITDA‑negative and is making targeted investments that constrain near‑term profitability. Key risks are backlog conversion timing, continued investment-driven cash burn and the potential need for further capital if revenue recognition lags recent contract wins.

Key Decisions for Investors

• Consider a selective buy or add-on exposure to benefit from demonstrable order‑book growth and identifiable contract wins such as the £3.5m phase III Huntington’s deal, but size positions modestly until conversion is visible
• Monitor quarterly metrics closely — order‑book conversion rates, timing of revenue recognition for recent large contracts, gross margin trends and cash runway — and require sustained EBITDA improvement before materially increasing exposure
• Prepare for dilution risk if operating losses persist despite the £3.7m raise; consider hedging or position limits and reassess after two consecutive quarters of positive cash flow or clear contract‑to‑revenue conversion